Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1590812

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1590812

Gastrointestinal Drugs Market by Drug Category (Acid Neutralizers, Anti-Inflammatory, Antiemetic & Antinauseants), Disease Type (Gastroesophageal Reflux Disorder, Irritable Bowel Syndrome), Route of Administration, End User - Global Forecast 2025-2030

PUBLISHED:
PAGES: 186 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Gastrointestinal Drugs Market was valued at USD 54.18 billion in 2023, expected to reach USD 57.27 billion in 2024, and is projected to grow at a CAGR of 5.78%, to USD 80.31 billion by 2030.

The scope of the gastrointestinal drugs market involves a broad focus on medications designed to treat a variety of digestive issues ranging from ulcers, inflammatory bowel disease, irritable bowel syndrome, to gastroesophageal reflux disease. This market is defined by the necessity of these medications to manage symptoms and improve the quality of life for millions of individuals worldwide. Application spans across prescriptions and over-the-counter medications used in hospitals, clinics, and homecare settings, with the end-use scope extending to both adult and pediatric populations. Market insights reveal a significant growth trajectory fueled by rising incidences of gastrointestinal disorders, increasing geriatric populations, and advancements in drug formulations. However, challenges such as stringent regulatory requirements, high costs of drug development, and potential side effects pose significant impediments to market expansion. Moreover, the COVID-19 pandemic has shifted priorities in healthcare allocations, impacting focus and funding toward non-urgent treatments. Opportunities abound in the development of biologics and biosimilars, personalized medicine approaches, and novel drug delivery systems like nanotechnology, which are expected to cater to unmet needs in treatment efficacy and patient compliance. To capitalize on these opportunities, companies should invest in R&D, focusing on innovative solutions that combine efficacy with minimal adverse reactions. They should also consider forging strategic alliances and collaborations to enhance their product pipeline and market reach. However, market players should remain cognizant of the competitive landscape characterized by high rivalry and the fast pace of technological evolution. The best areas for innovation and research include exploration into microbiome therapeutics and AI-driven patient stratification tools, allowing for tailored treatment plans. The nature of the gastrointestinal drugs market is dynamic, demanding continual innovation to address emerging challenges while maximizing therapeutic value and accessibility for patients globally.

KEY MARKET STATISTICS
Base Year [2023] USD 54.18 billion
Estimated Year [2024] USD 57.27 billion
Forecast Year [2030] USD 80.31 billion
CAGR (%) 5.78%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastrointestinal Drugs Market

The Gastrointestinal Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing geriatric population, changing lifestyles and eating habits
    • Development in biologics and a rising number of rectal related diseases
    • Drug development and rising awareness
  • Market Restraints
    • Side effects associated with the drugs
  • Market Opportunities
    • R&D activities to enhance drug development
    • Technological advancements in the treatment process
  • Market Challenges
    • Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome

Porter's Five Forces: A Strategic Tool for Navigating the Gastrointestinal Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastrointestinal Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastrointestinal Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastrointestinal Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastrointestinal Drugs Market

A detailed market share analysis in the Gastrointestinal Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastrointestinal Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastrointestinal Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastrointestinal Drugs Market

A strategic analysis of the Gastrointestinal Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayer AG, Boehringer Ingelheim GmbH, Eisai Co., Ltd., Eli Lilly & Co., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novo Nordisk A/S, Sanofi S.A., SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Limited, and ZERIA Pharmaceutical Co.,Ltd..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Category, market is studied across Acid Neutralizers, Anti-Inflammatory, Antiemetic & Antinauseants, Biologics, and Laxatives & Anti-diarrheal.
  • Based on Disease Type, market is studied across Gastroesophageal Reflux Disorder and Irritable Bowel Syndrome.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Rectal.
  • Based on End User, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-434CCDA051D0

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing geriatric population, changing lifestyles and eating habits
      • 5.1.1.2. Development in biologics and a rising number of rectal related diseases
      • 5.1.1.3. Drug development and rising awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D activities to enhance drug development
      • 5.1.3.2. Technological advancements in the treatment process
    • 5.1.4. Challenges
      • 5.1.4.1. Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gastrointestinal Drugs Market, by Drug Category

  • 6.1. Introduction
  • 6.2. Acid Neutralizers
  • 6.3. Anti-Inflammatory
  • 6.4. Antiemetic & Antinauseants
  • 6.5. Biologics
  • 6.6. Laxatives & Anti-diarrheal

7. Gastrointestinal Drugs Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Gastroesophageal Reflux Disorder
  • 7.3. Irritable Bowel Syndrome

8. Gastrointestinal Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Rectal

9. Gastrointestinal Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Retail Pharmacies

10. Americas Gastrointestinal Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Gastrointestinal Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Gastrointestinal Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bayer AG
  • 3. Boehringer Ingelheim GmbH
  • 4. Eisai Co., Ltd.
  • 5. Eli Lilly & Co.
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Novo Nordisk A/S
  • 9. Sanofi S.A.
  • 10. SFJ Pharmaceuticals Group
  • 11. SRS Life Sciences Pte. Ltd.
  • 12. Sun Pharmaceutical Industries Limited
  • 13. Takeda Pharmaceutical Company Limited
  • 14. Teva Pharmaceuticals Industries Limited
  • 15. ZERIA Pharmaceutical Co.,Ltd.
Product Code: MRR-434CCDA051D0

LIST OF FIGURES

  • FIGURE 1. GASTROINTESTINAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTROINTESTINAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GASTROINTESTINAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GASTROINTESTINAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ACID NEUTRALIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETIC & ANTINAUSEANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES & ANTI-DIARRHEAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!